Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 44
Filter
1.
Am J Physiol Lung Cell Mol Physiol ; 326(6): L812-L820, 2024 Jun 01.
Article in English | MEDLINE | ID: mdl-38712445

ABSTRACT

Chronic obstructive pulmonary disease (COPD) is a condition characterized by chronic airway inflammation and obstruction, primarily caused by tobacco smoking. Although the involvement of immune cells in COPD pathogenesis is well established, the contribution of innate lymphoid cells (ILCs) remains poorly understood. ILCs are a type of innate immune cells that participate in tissue remodeling processes, but their specific role in COPD has not been fully elucidated. During COPD, the breakdown of pulmonary elastin generates elastin peptides that elicit biological activities on immune cells. This study aimed to investigate the presence of ILC in patients with COPD and examine the impact of elastin peptides on their functionality. Our findings revealed an elevated proportion of ILC2 in the peripheral blood of patients with COPD, and a general activation of ILC as indicated by an increase in their cytokine secretion capacity. Notably, our study demonstrated that serum from patients with COPD promotes ILC2 phenotype, likely due to the elevated concentration of IL-5, a cytokine known to favor ILC2 activation. Furthermore, we uncovered that this increase in IL-5 secretion is partially attributed to its secretion by macrophages upon stimulation by elastin peptides, suggesting an indirect role of elastin peptides on ILC in COPD. These findings shed light on the involvement of ILC in COPD and provide insights into the potential interplay between elastin breakdown, immune cells, and disease progression. Further understanding of the mechanisms underlying ILC activation and their interaction with elastin peptides could contribute to the development of novel therapeutic strategies for COPD management.NEW & NOTEWORTHY Elastin-derived peptides, generated following alveolar degradation during emphysema in patients with COPD, are able to influence the response of type 2 innate lymphoid cells. We show that the orientation of innate lymphoid cells in patients with COPD is shifted toward a type 2 profile and that elastin peptides are indirectly participating in that shift through their influence of macrophages, which in turn impact innate lymphoid cells.


Subject(s)
Elastin , Immunity, Innate , Lymphocytes , Pulmonary Disease, Chronic Obstructive , Humans , Pulmonary Disease, Chronic Obstructive/immunology , Pulmonary Disease, Chronic Obstructive/pathology , Elastin/metabolism , Elastin/immunology , Lymphocytes/immunology , Lymphocytes/metabolism , Lymphocytes/drug effects , Female , Male , Aged , Middle Aged , Interleukin-5/metabolism , Interleukin-5/immunology , Macrophages/immunology , Macrophages/metabolism , Peptides/pharmacology , Peptides/immunology
2.
Phys Med Biol ; 67(18)2022 09 08.
Article in English | MEDLINE | ID: mdl-36001985

ABSTRACT

This paper reviews the ecosystem of GATE, an open-source Monte Carlo toolkit for medical physics. Based on the shoulders of Geant4, the principal modules (geometry, physics, scorers) are described with brief descriptions of some key concepts (Volume, Actors, Digitizer). The main source code repositories are detailed together with the automated compilation and tests processes (Continuous Integration). We then described how the OpenGATE collaboration managed the collaborative development of about one hundred developers during almost 20 years. The impact of GATE on medical physics and cancer research is then summarized, and examples of a few key applications are given. Finally, future development perspectives are indicated.


Subject(s)
Ecosystem , Software , Computer Simulation , Monte Carlo Method , Physics
3.
Adv Healthc Mater ; 10(16): e2100656, 2021 08.
Article in English | MEDLINE | ID: mdl-34212539

ABSTRACT

AGuIX are emerging radiosensitizing nanoparticles (NPs) for precision radiotherapy (RT) under clinical evaluation (Phase 2). Despite being accompanied by MRI thanks to the presence of gadolinium (Gd) at its surface, more sensitive and quantifiable imaging technique should further leverage the full potential of this technology. In this study, it is shown that 89 Zr can be labeled on such NPs directly for positron emission tomography (PET) imaging with a simple and scalable method. The stability of such complexes is remarkable in vitro and in vivo. Using a glioblastoma orthotopic rat model, it is shown that injected 89 Zr-AGuIX is detectable inside the tumor for at least 1 week. Interestingly, the particles seem to efficiently infiltrate the tumor even in necrotic areas, which places great hope for the treatment of radioresistant tumor. Lastly, the first PET/MR whole-body imaging is performed in non-human primate (NHP), which further demonstrates the translational potential of these bimodal NP.


Subject(s)
Glioblastoma , Nanoparticles , Animals , Contrast Media , Glioblastoma/diagnostic imaging , Humans , Macaca , Magnetic Resonance Imaging , Multimodal Imaging , Rats
4.
Phys Med Biol ; 66(10)2021 05 14.
Article in English | MEDLINE | ID: mdl-33770774

ABSTRACT

Built on top of the Geant4 toolkit, GATE is collaboratively developed for more than 15 years to design Monte Carlo simulations of nuclear-based imaging systems. It is, in particular, used by researchers and industrials to design, optimize, understand and create innovative emission tomography systems. In this paper, we reviewed the recent developments that have been proposed to simulate modern detectors and provide a comprehensive report on imaging systems that have been simulated and evaluated in GATE. Additionally, some methodological developments that are not specific for imaging but that can improve detector modeling and provide computation time gains, such as Variance Reduction Techniques and Artificial Intelligence integration, are described and discussed.


Subject(s)
Artificial Intelligence , Software , Computer Simulation , Monte Carlo Method , Tomography, X-Ray Computed
5.
J Clin Med ; 9(7)2020 Jul 07.
Article in English | MEDLINE | ID: mdl-32645862

ABSTRACT

Systemic sclerosis (SSc) is a systemic disease characterized by a great clinical and immunological heterogeneity whose pathophysiology is still being unraveled. Recently, innate immunity has been proposed to participate to the pathogenesis of SSc. In this study, we investigated the release of neutrophil extracellular traps (NETs) according to patient phenotype. Polymorphonuclear neutrophils (PMN) from 34 SSc patients and 26 healthy controls were stimulated by serum from SSc or healthy subject. NETs were visualized using epifluorescence microscope after DNA, myeloperoxidase, and Histone H3 tagging. Area of NETs were quantified using an original macro running in ImageJ® software. PMN from SSc patients were significantly more prone to releasing NETs than control PMN after autologous stimulation. PMN from patients with severe vascular complications (pulmonary arterial hypertension, digital ulcers) produced more NETs than PMN from other SSc patients and their aberrant NET production appeared to be sustained over time. In patients with pulmonary interstitial disease or extensive cutaneous fibrosis, NET production was high at an early stage of the disease before progressively decreasing. Both serum factors and PMN activation status were involved in the enhanced production of NETs in SSc. Consequently, neutrophils and especially NETosis represent new physiopathological and therapeutic fields in SSc.

6.
Front Immunol ; 10: 2107, 2019.
Article in English | MEDLINE | ID: mdl-31572359

ABSTRACT

Inflammation is largely implicated in bullous pemphigoid (BP), the most frequent skin auto-immune blistering disease. IL-17, essentially IL-17A/F, has been involved in blister formation through regulation of protease production, and its specific serum profile within BP was related to disease outcome. However, relationships between IL-17 family ligands and receptors are quite complex with six different IL-17 isoforms, and five different receptors. We here aimed at clarifying the contribution of the IL-17 axis in BP by characterizing not only the expression of IL-17 receptor (IL-17R) members within immune cells isolated from BP patients (PMNs, n = 9; T-lymphocytes, n = 10; and monocytes, n = 10) but also the expression of IL-17 isoforms in sera (n = 83), and blister fluid (n = 31) of BP patients. We showed that at diagnosis, IL-17RA and IL-17RC expression were significantly increased in monocytes isolated from BP patients as compared to those from control subjects (p = 0.006 and p = 0.016, respectively). Notably, both IL-17RA and IL-17RC mRNA expression remained elevated in BP monocytes at time of relapse. We further demonstrated a significant increase of all IL-17 isoforms tested in BP blister fluid compared with BP serum (IL-17A, p < 0.0001; IL-17A/F, p < 0.0001; IL-17B, p = 0.0023; IL-17C, p = 0.0022; IL-17E, p < 0.0001). Among all, IL-17B was the only cytokine for which a significant decreased concentration within blister fluid was observed in BP patients with severe disease compared to patients with moderate disease (p = 0.012). We further evidenced a significant negative correlation between IL-17B levels and blister/erosion BPDAI subscore (r = -0.52, p = 0.003). We finally identified mast cells as a potential target of IL-17B in lesional skin of BP patients. In conclusion, we showed here that IL-17RA and IL-17RC expression in monocyte was associated with disease activity and evidenced in situ a negative correlation between BP disease activity and IL-17B, whose effects could be mediated by IL-17RB expressed by mast cell in BP lesional skin.


Subject(s)
Macrophages/immunology , Mast Cells/immunology , Monocytes/immunology , Pemphigoid, Bullous/immunology , Receptors, Interleukin-17/immunology , Aged, 80 and over , Blister/immunology , Female , Humans , Inflammation/immunology , Male , Prospective Studies , RNA, Messenger/immunology , T-Lymphocytes/immunology
7.
Front Immunol ; 10: 1972, 2019.
Article in English | MEDLINE | ID: mdl-31507596

ABSTRACT

Bullous Pemphigoid (BP) is a skin autoimmune blistering disease characterized by immune-mediated degradation of the dermo-epidermal junction and release of a large number of inflammatory cytokines. Interleukin-1ß (IL-1ß) is a pleiotropic pro-inflammatory cytokine associated with inflammasome activation and known to be pivotal in several auto-immune and auto-inflammatory diseases. We sought to clarify the presence of inflammasome-dependent IL-1ß and to investigate its role in BP. Skin biopsy specimens (n = 13), serum (n = 60), blister fluid (n = 26), and primary inflammatory cells from patients with BP were used to investigate inflammasome activation and function. We here highlighted a differential occurrence of a functional in situ inflammasome in patients with BP, biologically distinguished by IL-1ß and NLRP3 expression. Clinically, elevated IL-1ß levels were associated with the presence of erythema and urticarial plaques reflecting the inflammatory phase preceding blister formation. We further identified IL-17 and IL-23 as important molecules favoring IL-1ß expression in monocyte-derived macrophages from BP patients. Finally, we demonstrated the ability of IL-1ß to stimulate the release of the matrix metalloproteinase-9 in those macrophages, reinforcing the role of IL-1ß in the auto-amplification loop of the inflammatory response associated to BP. However, whether this inflammasome is an epiphenomenon associated with BP disease or constitutes an amplification inflammatory step in certain patients still need to be determined. In the context of a precision medicine approach, our findings allowed us to delineate a subgroup of patients with BP that showed similarities with auto-inflammatory diseases. Subsequently, this opens up alternative therapeutic strategies targeting IL-1ß pathway in the aim to control the early, pre-blistering inflammatory phase. Ultimately, this could also help in reducing the detrimental effects associated with high doses of corticosteroids treatment.


Subject(s)
Inflammasomes/metabolism , Interleukin-17/metabolism , Interleukin-1beta/metabolism , Interleukin-23/metabolism , Macrophages/immunology , Macrophages/metabolism , Pemphigoid, Bullous/etiology , Pemphigoid, Bullous/metabolism , Aged , Aged, 80 and over , Autoantibodies/immunology , Biomarkers , Cytokines/metabolism , Disease Susceptibility , Female , Gene Expression , Humans , Male , Matrix Metalloproteinase 9 , Middle Aged , Pemphigoid, Bullous/diagnosis , Signal Transduction
8.
Front Immunol ; 10: 1858, 2019.
Article in English | MEDLINE | ID: mdl-31440247

ABSTRACT

Bullous pemphigoid (BP) is a cutaneous autoimmune disease, characterized by an inflammatory cascade leading to blister formation. Although macrophages were shown to participate in BP pathophysiology, their role in the blister formation process still needs to be investigated. We here addressed the influence of serum and blister fluid (BF) from patients with BP on the polarization status of macrophages with regards to the metalloproteinase-9 (MMP-9) expression. We demonstrated that several markers related to the alternatively activated macrophage phenotype (M2) including IL-10, TARC, arginase, TNFα, and IL-1RA were meaningfully increased in BF of patients with BP. We further showed that BF, but not serum from patients with BP, significantly induced the expression of CD163, CD206, and IL-10 in BP monocyte-derived macrophages (MDMs). Notably IL-10 was the only cytokine to be correlated to the reference clinical score, BP disease activity index (BPDAI), especially to the inflammatory BPDAI subscore evaluating urticarial and erythematous skin lesions (r = 0.57, p = 0.0004). We also found elevated levels of MMP-9 to M2-type macrophages ex vivo and highlighted the presence of CD163+ MMP-9+ macrophages histologically, at skin lesional site. Finally, we showed that methylprednisolone reduced MMP-9 levels in MDMs without modifying the other M2 markers. All together these results strongly support the presence of M2-phenotype macrophages with pro-inflammatory properties susceptible to favor blister formation in BP.


Subject(s)
Exudates and Transudates/immunology , Macrophage Activation/immunology , Macrophages/immunology , Matrix Metalloproteinase 9/immunology , Pemphigoid, Bullous/immunology , Blister/immunology , Humans
9.
Front Immunol ; 10: 701, 2019.
Article in English | MEDLINE | ID: mdl-31019514

ABSTRACT

Background: DNA extracellular traps (ETs), released by neutrophils (NETs), or eosinophils (EETs), play a pathogenic role in several autoimmune disorders. However, to date, NETs have never been investigated in bullous pemphigoid (BP) with respect to clinical and immunological activities, both at baseline and at time of relapse which have been characterized with specific IL-17 and IL-23 patterns. Objective: We sought to assess whether ETs were associated with BP as well as the relative contribution of IL-17 axis cytokines to NET induction. Methods: Skin biopsy specimens were obtained from 11 patients with BP. Immuno-detection of neutrophils and eosinophils combined to DNA staining allowed us to investigate the in-situ presence of NETs and EETs using confocal scanning microscopy. NETs release was evaluated ex vivo by stimulating polymorphonuclear cells from BP patients with BP biological fluids in presence of IL-17A and IL-23 or of glucocorticoids. Results: At baseline, ETs were observed in BP lesions at the site of dermal-epidermal cleavage. Despite an important infiltrate of eosinophils, ETs were essentially associated with neutrophils in situ and were not related to BP clinical activity at diagnosis. In situ observation of NETs was associated in 6 among 8 patients with serum capacity of NET induction. Notably both blister fluid and sera from BP patients at diagnosis and at time of relapse could induce NET formation ex vivo. In contrast, a longitudinal investigation showed a decrease of NET formation with time of treatment in patients undergoing remission. Mimicking relapse, complementation of sera from BP patients with ongoing remission with either IL-17A or IL-23 increased NET formation. Conversely, IL-17A inhibited NET formation induced by serum from BP patients with relapse supplemented or not with IL-23. Finally, glucocorticoids also inhibited NET formation ex vivo in BP. Conclusion: NET formation is an associated phenomenon with BP. Furthermore, we showed that IL-23 favored NET formation, whereas the effects of IL-17A are environment dependent. Indeed, IL-17A displayed a protective effect on NET formation when associated with IL-23, showing for the first-time differential effects of these two cytokines in BP.


Subject(s)
Extracellular Traps/immunology , Interleukin-17/blood , Interleukin-23 Subunit p19/blood , Pemphigoid, Bullous/immunology , Acetates/pharmacology , Aged , Aged, 80 and over , Anti-Inflammatory Agents/pharmacology , Eosinophils/immunology , Extracellular Traps/drug effects , Extracellular Traps/metabolism , Female , Humans , Male , Methylprednisolone/pharmacology , Middle Aged , Neutrophils/immunology , Pemphigoid, Bullous/blood , Pemphigoid, Bullous/drug therapy , Prospective Studies , Recurrence , Translational Research, Biomedical , Tyramine/analogs & derivatives , Tyramine/pharmacology
10.
Exp Dermatol ; 28(5): 593-600, 2019 05.
Article in English | MEDLINE | ID: mdl-30903721

ABSTRACT

Hidradenitis suppurativa/acne inversa (HS) is a chronic, inflammatory, recurrent, debilitating skin disease of the hair follicle, associated with considerable tissue remodelling. Although abnormal cytokine expression was detected both in perilesional and in uninvolved skin, up to now there is no model allowing a better understanding of the implicit inflammatory mechanisms in HS. The aim of this study was to investigate the inflammatory response in HS skin by mean of an ex vivo model culture. To that purpose, nine skin biopsy specimens from patients suffering from HS and controls were cultured up to 4 days. Microscopy imaging investigations showed variations of collagen I and III organization, and an increase in elastin fibres fragmentation in HS skin after 4 days of culture. The HS matrix structure remodelling was associated with high level of MMP-2 and MMP-9 in HS lesional skin. After 4 days of culture, the MMP expression in HS perilesional skin reached the level observed in HS lesional skin. Concomitantly, an increase in IL-1ß concentration was observed in all skin samples after 4 days of culture, although IL-1ß concentrations remained significantly higher in HS lesional skin as compared with control skin. Meanwhile, neither IL-17 concentrations nor the inflammasome components NLRP3 and caspase-1 varied. Thus, our HS skin model culture showed that MMP-induced matrix alteration could participate in HS inflammation by releasing biological active peptides and inflammatory factors from the extracellular matrix (ECM), and open new opportunities to investigate the regulation of the inflammatory mechanism associated with HS.


Subject(s)
Extracellular Matrix/metabolism , Gene Expression Regulation, Enzymologic , Hidradenitis Suppurativa/metabolism , Matrix Metalloproteinase 2/metabolism , Matrix Metalloproteinase 9/metabolism , Adult , Biopsy , Caspase 1/metabolism , Cell Culture Techniques , Cells, Cultured , Cytokines/metabolism , Female , Humans , Inflammasomes/metabolism , Inflammation , Male , Middle Aged , NLR Family, Pyrin Domain-Containing 3 Protein/metabolism , Skin/metabolism , Skin/pathology
11.
Article in English | MEDLINE | ID: mdl-33304614

ABSTRACT

PURPOSE: We are investigating the use of promptly emitted Cerenkov photons to improve scintillation detector timing resolution for time-of-flight (TOF) positron emission tomography (PET). Bismuth germanate (BGO) scintillator was used in most commercial PET scanners until the emergence of lutetium oxyorthosilicate, which allowed for TOF PET by triggering on the fast and bright scintillation signal. Yet BGO is also a candidate to generate fast timing triggers based on Cerenkov light produced in the first few picoseconds following a gamma interaction. Triggering on the Cerenkov light produces excellent timing resolution in BGO but is complicated by the very low number of photons produced. A better understanding of the transport and collection of Cerenkov photons is needed to optimize their use for effective triggering of the detectors. METHODS: We simultaneously generated and tracked Cerenkov and scintillation photons with a new model of light transport that we have released in GATE V8.0. This crystal reflectance model was used to study photon detection and timing properties, building realistic waveforms as measured with silicon photomultipliers. RESULTS: We compared the behavior and effect of detecting Cerenkov and scintillation photons at several levels, including detection time stamps, travel time, and coincidence resolving time in 3 × 3 × 20 mm3 BGO crystals. Simulations showed excellent agreement with experimental results and indicated that Cerenkov photons constitute the majority of the signal rising edge. They are therefore critical to provide early triggering and improved the coincidence timing resolution by 50%. POTENTIAL APPLICATIONS: To our knowledge, this is the first complete simulation of the generation, transport, and detection of the combination of Cerenkov and scintillation photons for TOF detectors. This simulation framework will allow for quantitative study of the factors influencing timing resolution, including the photodetector characteristics, and ultimately aid the development of BGO and other Cerenkov-based detectors for TOF PET.

12.
Front Immunol ; 9: 479, 2018.
Article in English | MEDLINE | ID: mdl-29662486

ABSTRACT

Bullous pemphigoid (BP) is the most common autoimmune bullous disease and typically affects the elderly. Binding of specific autoantibodies to BP180/230 hemidesmosomal components induces an inflammatory response leading to skin blister formation. Unusual manifestations of BP include additional mucous membrane involvement, without pathophysiological knowledge associated to the formation of these lesions. We here performed a prospective study on series of consecutive BP patients with (n = 77) and without (n = 18) mucosal involvements at baseline to further investigate why some BP patients display mucosal lesion and other not. Analysis of disease activity showed that BP patients with mucosal involvement displayed a higher total BP Disease Area Index (BPDAI) score (P = 0.008), but also higher skin and blister/erosion BPDAI scores (P = 0.02 and P = 0.001, respectively). By contrast, the erythema/urticaria BPDAI score was identical between the two groups of patients. The erythema/urticaria BPDAI score, but not the blister/erosion BPDAI score, was correlated with the serum concentration of anti-BP180 NC16A autoantibodies in patients with mucosal involvement. In multivariate analysis, the absence of anti-BP230 autoantibody was the only factor independently associated with mucosal involvement (OR 7.8; 95% CI, 3.1-19.6) (P < 0.0001). Analysis of the distribution of BP patients according to BPDAI scores revealed a shift toward higher blister/erosion BPDAI scores for BP patients with mucosal involvement. This study indicates that mucosal lesions are clinically mainly related to disease severity and immunologically to the absence of anti-BP230 antibodies.


Subject(s)
Autoantibodies/immunology , Dystonin/immunology , Immunity, Mucosal , Pemphigoid, Bullous/immunology , Aged , Aged, 80 and over , Female , Humans , Male , Mucous Membrane/immunology , Mucous Membrane/pathology , Pemphigoid, Bullous/pathology , Severity of Illness Index
13.
Front Immunol ; 9: 570, 2018.
Article in English | MEDLINE | ID: mdl-29619029

ABSTRACT

Bullous pemphigoid (BP) is an autoimmune bullous skin disease characterized by anti-BP180 and anti-BP230 autoantibodies (AAbs). Mucous membrane involvement is an uncommon clinical feature of BP which may evoke epidermolysis bullosa acquisita, another skin autoimmune disease characterized by anti-type VII collagen AAbs. We therefore evaluated the presence of anti-type VII collagen AAbs in the serum of BP patients with and without mucosal lesions at time of diagnosis and under therapy. Anti-BP180, anti-BP230, and anti-type VII collagen AAbs were measured by ELISA in the serum of unselected patients fulfilling clinical and histo/immunopathological BP criteria at baseline (n = 71) and at time of relapse (n = 24). At baseline, anti-type VII collagen AAbs were detected in 2 out of 24 patients with BP presenting with mucosal involvement, but not in patients without mucosal lesions (n = 47). At the time of relapse, 10 out of 24 BP patients either displayed a significant induction or increase of concentrations of anti-type VII collagen AAbs (P < 0.01), independently of mucosal involvement. Those 10 relapsing BP patients were also characterized by a sustained high concentration of anti-BP180 AAb, whereas the serum anti-BP230 AAb concentrations did not vary in BP patients with relapse according to the presence of anti-type VII collagen AAbs. Thus, our study showed that anti-type VII collagen along with anti-BP180 AAbs detection stratified BP patients at time of relapse, illustrating a still dysregulated immune response that could reflect a potential epitope spreading mechanism in those BP patients.


Subject(s)
Autoantibodies/immunology , Collagen Type VII/immunology , Pemphigoid, Bullous/immunology , Skin/immunology , Aged , Aged, 80 and over , Autoantibodies/blood , Enzyme-Linked Immunosorbent Assay , Female , Humans , Male , Middle Aged , Mucous Membrane/immunology , Mucous Membrane/metabolism , Pemphigoid, Bullous/blood , Pemphigoid, Bullous/metabolism , Recurrence , Retrospective Studies , Skin/metabolism , Skin/pathology
14.
Exp Dermatol ; 26(12): 1240-1247, 2017 12.
Article in English | MEDLINE | ID: mdl-29105148

ABSTRACT

Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease of the skin. Investigation of the BP-associated pathophysiological processes during the last decades showed that the generation of autoantibodies directed against the hemidesmosome proteins BP180 and BP230, a hallmark of the BP-associated autoimmune response, leads to the recruitment of inflammatory immune cells at the dermal-epidermal junction, and subsequently to the release of a large amount of inflammatory molecules involved in blister formation. Analysis in transversal and longitudinal studies of autoantibodies and inflammatory molecules production both at the time of diagnosis and under treatment was mainly performed within the serum but also in the blister fluid. Some autoimmune or inflammatory molecules expression was related to the presence of clinical signs, while others were mere bystanders. In this review, we focused on the autoimmune and inflammatory molecules that have been identified as potential biomarkers of BP development and outcome.


Subject(s)
Autoantibodies/metabolism , Biomarkers/metabolism , Pemphigoid, Bullous/immunology , Animals , Humans , Inflammation/metabolism , Pemphigoid, Bullous/metabolism
15.
Exp Dermatol ; 26(12): 1261-1266, 2017 12.
Article in English | MEDLINE | ID: mdl-28887823

ABSTRACT

Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease in Western countries. Although topical and/or systemic glucocorticoids treatment efficacy is widely recognized, up to 30% of patients with BP may undergo a relapse during the first year of treatment. We investigated the protein expression of the total glucocorticoid receptor and GRß isoform in the skin biopsy specimens from patients with BP and wondered whether such investigation at baseline provided a tool to predict disease outcome. Total GR and GRß protein expressions were detected by immunohistochemistry at baseline on 12 patients who later relapse and 11 patients who remained on remission in comparison with 14 control patients. The expression of GRß in the epidermis of patients with BP who later relapse was significantly higher than that in the epidermis of patients with BP controlled upon corticosteroid treatment, which was also higher than control patients. Thus, our results suggest that increased protein expression of GRß in skin epithelial cells is predictive of reduced steroid treatment efficacy, and therefore of increased risk of disease relapse in patients with BP.


Subject(s)
Glucocorticoids/therapeutic use , Pemphigoid, Bullous/metabolism , Receptors, Glucocorticoid/metabolism , Aged , Aged, 80 and over , Case-Control Studies , Female , Humans , Male , Middle Aged , Pemphigoid, Bullous/drug therapy , Recurrence
16.
Sci Rep ; 7(1): 4833, 2017 07 06.
Article in English | MEDLINE | ID: mdl-28684769

ABSTRACT

Bullous Pemphigoid (BP) is an inflammatory rare autoimmune bullous dermatosis, which outcome cannot be predicted through clinical investigations. Eosinophils are the main immune infiltrated cells in BP. However, the release of Major Basic Protein (MBP), Eosinophil Derived Neurotoxin (EDN), and Eosinophil Cationic Protein (ECP) upon eosinophil activation has still not been evaluated with respect to BP development. MBP, EDN and ECP were measured by ELISA in serum (n = 61) and blister fluid (n = 20) of patients with BP at baseline, and in serum after 2 months of treatment (n = 41). Eosinophil activation in BP patients was illustrated at baseline by significantly higher MBP, EDN and ECP serum concentrations as compared with control subjects (n = 20), but without distinction according to disease severity or outcome. EDN and ECP values were even higher in the blister fluids (P < 0.01 and P < 0.05, respectively), whereas MBP values were lower (P < 0.001). ECP serum concentration decreased after 60 days of treatment in BP patients with ongoing remission but not in patients who later relapsed (P < 0.05). A reduction of at least 12.8 ng/mL in ECP concentrations provided a positive predictive value for remission of 81%, showing that ECP serum variation could be a useful biomarker stratifying BP patients at risk of relapse.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Clobetasol/therapeutic use , Eosinophil Cationic Protein/genetics , Eosinophils/drug effects , Pemphigoid, Bullous/diagnosis , Pemphigoid, Bullous/drug therapy , Aged , Aged, 80 and over , Biomarkers/blood , Case-Control Studies , Cell Movement/drug effects , Eosinophil Cationic Protein/blood , Eosinophil Cationic Protein/immunology , Eosinophil Major Basic Protein/blood , Eosinophil Major Basic Protein/genetics , Eosinophil Major Basic Protein/immunology , Eosinophil-Derived Neurotoxin/blood , Eosinophil-Derived Neurotoxin/genetics , Eosinophil-Derived Neurotoxin/immunology , Eosinophils/immunology , Eosinophils/pathology , Female , Gene Expression , Humans , Male , Pemphigoid, Bullous/genetics , Pemphigoid, Bullous/immunology , Predictive Value of Tests , Prognosis , Prospective Studies , Recurrence , Remission Induction , Severity of Illness Index , Survival Analysis , Treatment Outcome
17.
Biomed Opt Express ; 8(3): 1665-1681, 2017 Mar 01.
Article in English | MEDLINE | ID: mdl-28663855

ABSTRACT

Application of nanotechnology for biomedicine in cancer therapy allows for direct delivery of anticancer agents to tumors. An example of such therapies is the nanoparticle-mediated near-infrared hyperthermia treatment. In order to investigate the influence of nanoparticle properties on the spatial distribution of heat in the tumor and healthy tissues, accurate simulations are required. The Geant4 Application for Emission Tomography (GATE) open-source simulation platform, based on the Geant4 toolkit, is widely used by the research community involved in molecular imaging, radiotherapy and optical imaging. We present an extension of GATE that can model nanoparticle-mediated hyperthermal therapy as well as simple heat diffusion in biological tissues. This new feature of GATE combined with optical imaging allows for the simulation of a theranostic scenario in which the patient is injected with theranostic nanosystems that can simultaneously deliver therapeutic (i.e. hyperthermia therapy) and imaging agents (i.e. fluorescence imaging).

18.
EJNMMI Phys ; 4(1): 16, 2017 Dec.
Article in English | MEDLINE | ID: mdl-28466279

ABSTRACT

BACKGROUND: The correction of γ-photon attenuation in PET-MRI remains a critical issue, especially for bone attenuation. This problem is of great importance for brain studies due to the density of the skull. Current techniques for skull attenuation correction (AC) provide indirect estimates of cortical bone density, leading to inaccurate estimates of brain activity. The purpose of this study was to develop an alternate method for bone attenuation correction based on NMR. The proposed approach relies on the detection of hydroxyapatite crystals by zero echo time (ZTE) MRI of 31P, providing individual and quantitative assessment of bone density. This work presents a proof of concept of this approach. The first step of the method is a calibration experiment to determine the conversion relationship between the 31P signal and the linear attenuation coefficient µ. Then 31P-ZTE was performed in vivo in rodent to estimate the µ-map of the skull. 18F-FDG PET data were acquired in the same animal and reconstructed with three different AC methods: 31P-based AC, AC neglecting the bone and the gold standard, CT-based AC, used to comparison for the other two methods. RESULTS: The calibration experiment provided a conversion factor of 31P signal into µ. In vivo 31P-ZTE made it possible to acquire 3D images of the rat skull. Brain PET images showed underestimation of 18F activity in peripheral regions close to the skull when AC neglected the bone (as compared with CT-based AC). The use of 31P-derived µ-map for AC leads to increased peripheral activity, and therefore a global overestimation of brain 18F activity. CONCLUSIONS: In vivo 31P-ZTE MRI of hydroxyapatite provides µ-map of the skull, which can be used for attenuation correction of 18F-FDG PET images. This study is limited by several intrinsic biases associated with the size of the rat brain, which are unlikely to affect human data on a clinical PET-MRI system.

19.
Phys Med Biol ; 62(12): L1-L8, 2017 Jun 21.
Article in English | MEDLINE | ID: mdl-28452339

ABSTRACT

Typical PET detectors are composed of a scintillator coupled to a photodetector that detects scintillation photons produced when high energy gamma photons interact with the crystal. A critical performance factor is the collection efficiency of these scintillation photons, which can be optimized through simulation. Accurate modelling of photon interactions with crystal surfaces is essential in optical simulations, but the existing UNIFIED model in GATE is often inaccurate, especially for rough surfaces. Previously a new approach for modelling surface reflections based on measured surfaces was validated using custom Monte Carlo code. In this work, the LUT Davis model is implemented and validated in GATE and GEANT4, and is made accessible for all users in the nuclear imaging research community. Look-up-tables (LUTs) from various crystal surfaces are calculated based on measured surfaces obtained by atomic force microscopy. The LUTs include photon reflection probabilities and directions depending on incidence angle. We provide LUTs for rough and polished surfaces with different reflectors and coupling media. Validation parameters include light output measured at different depths of interaction in the crystal and photon track lengths, as both parameters are strongly dependent on reflector characteristics and distinguish between models. Results from the GATE/GEANT4 beta version are compared to those from our custom code and experimental data, as well as the UNIFIED model. GATE simulations with the LUT Davis model show average variations in light output of <2% from the custom code and excellent agreement for track lengths with R 2 > 0.99. Experimental data agree within 9% for relative light output. The new model also simplifies surface definition, as no complex input parameters are needed. The LUT Davis model makes optical simulations for nuclear imaging detectors much more precise, especially for studies with rough crystal surfaces. It will be available in GATE V8.0.


Subject(s)
Monte Carlo Method , Optical Phenomena , Photons , Scintillation Counting , Positron-Emission Tomography
20.
Int J Oncol ; 50(2): 717-726, 2017 Feb.
Article in English | MEDLINE | ID: mdl-28035377

ABSTRACT

Glucocorticoids are largely used in the treatment of inflammatory pathologies and/or hematological malignancies and regulate the expression of a variety of genes involved in inflammation or metastasis such as matrix metalloproteinases (MMP). Long-term exposure to glucocorticoids can result in failure of responsiveness, which is often associated with an unwanted gene expression. Epigenetic mechanisms are involved in gene expression modulated after development of glucocorticoid resistance but how these mechanisms take place must be further studied. The effects of HDAC inhibitors (HDACi) in a context of glucocorticoid resistance are still not well understood and need to be further investigated. We hypothesized that acquired glucocorticoid resistance associated to HDACi could disturbs epigenetic landscape, especially miR expression, leading to a modulation of MMP-9 gene expression and/or protein secretion, described as largely involved in bone remodeling and tumor invasion in multiple myeloma. To this aim, we used sensitive RPMI-8226 cell line and its dexamethasone- and methylprednisolone-resistant derivatives. The resistant cell lines displayed an 'open chromatin' and an MMP-9 overexpression comparatively to the sensitive cell line. HDACi treatment with MS-275 increased even more MMP-9 overexpression not only at an mRNA level but also at the protein level. We showed that MMP-9 expression regulation was not directly linked with HAT/HDAC balance alterations but rather with the deregulation of MMP-9-targeting miRs. Then, we first demonstrated that miR­149 downregulation was directly involved in the MMP-9 overexpression following a chronic glucocorticoid exposure and that MS-275 could amplify this overexpression by inhibition of miR­149 expression and miR­520c overexpression. Taken together, these results indicate that the use of HDACi in a context of acquired glucocorticoid resistance could modify the epigenetic landscape, highlighting the importance of taking the glucocorticoid response status into consideration in treatment with HDACi.


Subject(s)
Glucocorticoids/pharmacology , Histone Deacetylase Inhibitors/pharmacology , Matrix Metalloproteinase 9/genetics , Matrix Metalloproteinase 9/metabolism , MicroRNAs/genetics , Multiple Myeloma/genetics , Benzamides/pharmacology , Cell Line , Dexamethasone/pharmacology , Drug Resistance, Neoplasm , Epigenesis, Genetic/drug effects , Gene Expression Regulation, Neoplastic/drug effects , Histone Deacetylases/metabolism , Humans , Methylprednisolone/pharmacology , Multiple Myeloma/metabolism , Pyridines/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...